FORM PTO-1449 (modified)
To: U.S. Department of Commerce
(PW FORM PAT-1449)
Patent and Trademark Office

Atty. Dkt No.	M#	Client Ref.
	037003-0280705	1995-30-0233CP3

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Applicant ANDERSON, et al.

Appln. No 10/073,138

Filing Date: February 13, 2002

Examiner: Gambel, P. Group Art Unit: 1644

Date: February 6, 2004 Page 1 of 3

U.S. PATENT DOCUMENTS

Examiner's Initials*		Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)
PG	AR	4,816,397	03/1989	Boss, et al.	435	68	
	BR	4,816,567	03/1989	Cabilly, et al	530	387	
	CR	5,116,964	05/1992	Capon, et al.	536	27	
	DR	5,844,095	12/1998	Linsley, et al			
	ER	5,885,579	03/1999	Linsley, et al.			
	FR	6,051,228	04/2000	Aruffo, et al.			
	GR	6,162,432	12/2000	Wallner, Et al			

FOREIGN PATENT DOCUMENTS

		Document Number	Date MM/YYYY	Country	Inventor Name	English Abstract		Translation Readily Available	
						Enclosed	No	Enclose	
	HR	0 171 496 B1	05/1993	EP	Taniguchi, et al				
	IR	0 173 494 A2	03/1986	EP	Morrison, et al.				
	JR	0 239 400 B1	08/1994	EP	Winter, et al.				
	KR	0 194 276 A1	03/1986	EP	Neuberger, et al				
	LR	0 451 216 B1	10/1991	EP	Queen, et al.				
	MR	0 555 880 A2, A3	08/1993	EP	Aruffo, et al.				
	NR	0 682 040 A1	11/1995	EP	Queen, et al.				
	OR	2 177 096 A	03/1986	GB	Neuberger, et al				
	PR	WO 92/06193	04/1992	WO	Gorman, et al.				
	QR	WO 93/09812	05/1993	WO	Lederman, et al				
	RR	WO 94/28912	12/1994	WO	Thompson, et al.				
	SR	WO 95/06481	03/1995	WO	Noelle, et al.				
	TR	WO 95/08686	03/1995	WO	Noelle, et al.				
	UR	WO 98/19706	05/1998	WO	Anderson, et al.				

OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)

	VR	Armitage, et al., "Molecular and biological characterization of a murine," *Nature*, 1992, 357 80—82.
	WR	Ben-Nun, et al . "The rapid isolation of clonable antigen-specific T lymphocyte lines capable of mediating autoimmune encephalomyelitis," *Eur. J. Immunol.*, 1981, 11, 195-199
	XR	Blazar, et al., "Infusion of anti-B7.1 (CD80) and anti-B7 2 (CD86) monoclonal antibodies inhibits murine graft-versus-host disease lethality in part via direct effects on CD4+ and CD8+ T cells," *J. Immunol.*, 1996, 157 3250-3259
	YR	Capon, et al., "Designing CD4 immunoadhesins for AIDS therapy," *Nature*, 1989, 337, 525—531.
	ZR	Cohen, J., New protein steals the show as 'costimulator' of T cells, Science, (1993) 262 844-845.

PHILLIP GAMBEL 2/14/05

	AAR	Dautigny, et al., "Molecular cloning and nucleotide sequence of a cDNA clone coding for rat brain myelin proteolipid," *FEBS Lett.*, 1985, 188(1):33-36.
	BBR	Delabie, et al., "The B7/BB1 antigen is expressed by Reed-Sternberg cells of Hodgkin's disease and contributes to the stimulating capacity of Hodgkin's disease-derived cell lines," *Blood*, 1993, 82:2845-52.
	CCR	Dillman, et al., "Antibodies as cytotoxic therapy," *J Clin. Oncol.*, 1994, 12 1497-1515.
	DDR	Durie, et al., "The role of CD40 and its ligand (gp39) in peripheral and central tolerance and its contribution to autoimmune disease," *Research in Immunology*, 1994, 145(3), 200-205 & 244-249.
	EER	Durie, et al., "Prevention of collagen-induced arthritis with an antibody to gp39, the ligand for CD40," *Science*, 1993, 261:1328-1330.
	FFR	Falini, et al., "Response of refractory Hodgkin's disease to monoclonal anti-CD30 immunotoxin," *Lancet*, 1992, 339:1195-1196.
	GGR	Freeman, et al., "Uncovering of functional alternative CTLA-4 counter-receptor in B7-deficient mice," *Science*, 1993, 262:907-909.
	HHR	Freeman, et al., "Cloning of B7-2: a CTLA-4 counter-receptor that costimulates human T cell proliferation," *Science*, 1993, 262 909-911
	IIR	Gerritse, et al., "CD40-CD40 ligand interactions in experimental allergic encephalomyelitis and multiple sclerosis," *Proc. Natl. Acad. Sci. USA*, 1996, 93:2499-2504.
	JJR	Gottlieb, et al., "Results of a single-dose dose-escalating trial of an anti-B7.1 antibody (IDEC-114) in patients with psoriasis," *J. Invest. Dermatol.*, 2000, 114:840, Abstract No. 546.
	KKR	Gottlieb, et al., "Clinical and histologic response to single-dose treatment of moderate to severe psoriasis with an anti-CD80 monoclonal antibody," *J. Am. Acad. Dermatol.*, 2002, 47:693-700.
	LLR	Guinan, et al., "Pivotal role of the B7:CD28 pathway in transplantation tolerance and tumor immunity," *Blood*, 1994, 84:3261-3282
	MMR	Hafler, et al., "The potential of restricted T cell recognition of myelin basis protein epitopes in the therapy of multiple sclerosis," *Ann. NY Acad. Sci.*, 1991, 636:251-265
	NNR	Hariharan, et al., "Therapeutic activity of IDEC-114 (anti-CD80) and rituximab (Rituxan®) in B-cell lymphoma," *Blood*, 2001, 98 (11 part 1), p. 608a (abstract).
	OOR	Hathcock, et al., "Identification of an alternative CTLA-4 ligand costimulatory for T cell activation," *Science*, 1993, 262:905-907.
	PPR	Hollenbaugh, et al., "The human T cell antigen gp39, a member of the TNF gene family, is a ligand for the CD40 receptor: expression of a soluble form of gp39 with B cell co-stimulatory activity," *EMBO J.*, 1992, 11(12) 4313-4321
	QQR	Kahan, "Immunosuppressive therapy," *Curr Opin Immunol.*, 1992, 4:553-560.
	RRR	Karpus, et al., "CD4+ suppressor cells differentially affect the production of IFN-γ by effector cells of experimental autoimmune encephalomyelitis," *J. Immunol.*, 1989, 143:3492-3497.
	SSR	Kuntz, "Structure-based strategies for drug design and discovery," *Science*, 1992, 257:1078-82.
	TTR	Laman, et al., "The role of gp39 (CD40 ligand) in EAE and MS," *Journal of Neuroimmunology*, 1994, 54(1-2):175.
	UUR	Lederman, et al., "Identification of a novel surface protein on activated CD4+ T cells that induces contact-dependent B cell differentiation (Help)," *J Exp. Med.*, 1992, 175:1091-1101
	VVR	Lider, et al., "Suppression of experimental autoimmune encephalomyelitis by oral administration of myelin basic protein," *J. Immunol.*, 1989, 142:748-752
	WWR	Linsley, et al., "The role of the CD28 receptor during T cell responses to antigen," *Ann. Rev Immunol.*, 1993, 11:191-212.
	XXR	Liu, et al., "Blockade of CD28/CTLA-4-B7 co-stimulatory pathway in colitic SCID mice," *Digestive Disease Week*, May 21-24, 2000, p A58, Abstract No. 3000
	YYR	McCafferty, et al., " Phage antibodies: filamentous phage displaying antibody variable domains," *Nature*, 1990, 348 552-554
	ZZR	Miller, et al., "Antigen-driven bystander suppression after oral administration of antigens," *J Exp. Med.*, 1991, 174:791-798.
	AAAR	Mokhtarian, et al., "Adoptive transfer of myelin basic protein-sensitized T cells produces chronic relapsing demyelinating disease in mice," *Nature*, 1984, 309:356-358.
	BBBR	Morrison, et al., "Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains," *Proc. Natl Acad. Sci USA*, 1985, 81:6851-6855.
	CCCR	Munro, et al., "In vivo expression of the B7 costimulatory molecule by subsets of antigen-presenting cells and the malignant cells of Hodgkin's disease," *Blood*, 1994, 83:793-798
	DDDR	Ngo, et al., in Merz, Jr. and Le Grand (eds), The Protein Folding Problem and Tertiary Structure Prediction, Birkhauser, Boston, MA, pp. 433 & 492-495

PHILLIP GAMBER 2/04/05

10/ 073138

	EEER	Nickoloff, et al., "T lymphocytes in skin lesions of psoriasis and mycosis fungoides express B7-1: a ligand for CD28," *Blood*, 1994, 83:2580-2586.
	FFFR	Noelle, et al., "A 39-kDa protein on activated helper T cells binds CD40 and transduces the signal for cognate activation of B cells," *Proc. Natl. Acad. Sci. USA*, 1992, 89:6550-6554.
	GGGR	Olsson, et al., "Human-human monoclonal antibody-producing hybridomas: technical aspects," *Meth. Enzymol.*, 1982 92 3-17.
	HHHR	Perrin, et al., "Opposing effects of CTLA4-Ig and anti-CD80 (B7-1) plus anti-CD86 (B7-2) on experimental allergic encephalomyelitis," *J. Neuroimmunol.*, 1996, 65:31-39.
	IIIR	Pesoa, et al., Regulation of experimental allergic encephalomyelitis Part 5. Role of the recepient in suppressor cell induction, *J. Neuroimmunol.*, 1984, 7 131-135.
	JJJR	Pettinelli, et al., "Adoptive transfer of experimental allergic encephalomyelitis in SJL/J mice after *in vitro* activation of lymph node cells by myelin basic protein: requirement for Lyt 1⁺ 2⁻ T lymphocytes," *J. Immunol.*, 1979, 127:1420-1423.
	KKKR	Skolnick, et al., "From genes to protein structure and function: novel applications of computational approaches in the genomic era," *Trends in Biotechnology*, 2000, 18:34-9
	LLLR	Sobel, et al., "Acute experimental allergic encephalomyelitis in SJL/J mice induced by a synthetic peptide of myelin proteolipid protein," *J. Neuropathol. Exp. Neurol.*, 1990, 49(5):468-479.
	MMMR	Stamenkovic, et al., "A B-lymphocyte activation molecule related to the nerve growth factor receptor and induced by cytokines in carcinomas," *EMBO J.*, 1989, 8(5),1403-1410.
	NNNR	Suvas, et al., "Distinct role of CD80 and CD86 in the regulation of the activation of B cell and B cell lymphoma," *J. Biol. Chem.*, 2002 277:7766-7775.
	OOOR	Takeda, et al., "Construction of chimaeric processed immunoglobulin genes containing mouse variable and human constant region sequences," *Nature*, 1985, 314(4):452-454.
	PPPR	Teng, et al., "Construction and testing of mouse-human heteromyelomas for human monoclonal antibody production," *Proc. Natl. Acad. Sci. USA*, 1983, 80:7308-7312.
	QQQR	Tuohy, et al., "Identification of an encephalitogenic determinant of myelin proteolipid protein for SJL mice," *J. Immunol.*, 1989, 142.1523-1527.
	RRRR	Van der Veen, et al., "The adoptive transfer of chronic relapsing experimental allergic encephalomyelitis with lymph node cells sensitized to myelin proteolipid protein," *J. Neuroimmunol.*, 1989, 21:183-191.
	SSSR	Ward, et al., "Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coli," *Nature*, 1989, 341 544-546.
	TTTR	Ward, et al., "Blocking of adhesion molecules in vivo as anti-inflammatory therapy," *Ther. Immunol.*, 1994, 1:165-171.
	UUUR	Yi-qun, et al., "Differential requirements for co-stimulatory signals from B7 family members by resting versus recently activated memory T cells towards soluble recall antigens," *Int. Immunol.*, 1996, 8 37-44.

Examiner	Date Considered:

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

2/14/05

FORM PTO-1449 (modified)



Atty. Ref. No.	Client Ref.
037003-0280705	1995-30-0233CP3

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Applicant: ANDERSON et al.

Appln. No.: 10/073,138

Filing Date: February 13, 2002

Date: October 15, 2004 Page 1 of 2

Examiner: Gambel, P. Group Art Unit: 1644

U.S. PATENT DOCUMENTS

Examiner's Initials*		Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)
PG	AR	5,304,635	04/1994	Imam			
	BR						
	CR						

FOREIGN PATENT DOCUMENTS

		Document Number	Date MM/YYYY	Country	Inventor Name	English Abstract		Translation Readily Available	
						Enclosed	No	Enclose	No
	DR								
	ER								
	FR								

OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)

PG	GR	Alegre M., et al, "Effect of single amino acid mutation on the activating and immunosuppressive properties of a "Humanized" OKT3 monoclonal antibody," J. Immunol., 1992, 148:3461-3468.
	HR	Azuma M., et al., "CD28 Interaction with B7 Costimulates Primary Allogeneic Proliferative Responses and Cytotoxicity Mediated by Small Resting T Lymphocytes," J. Exp. Med., 1992, 175:353-360.
	IR	Azuma M., et al., "Functional Expression of B7/BB1 on Activated T Lymphocytes," J. Exp. Med., 1993, 177:845-850.
	JR	Azuma M.D., et al., "B70 Antigen is a Second Ligand for CTLA-4 and CD28," Nature, 1993, 366:76-79.
	KR	Boussiotis V.A., et al., "Activated human B lymphocytes express three CTLA-4 counter-receptors that co-stimulate T-Cell activation," Proc. Natl. Acad. Sci., USA, 1993, 90:11059-11063.
	LR	Cohen J., "Mounting a targeted strike on unwanted immune responses," (news; comment), Science, 1992, 257:751.
	MR	De Boer M., et al., "Functional Characterization of a Novel Anti-B7 Monoclonal Antibody," Eur. Journal of Immunology, 1992, 22:3071-3075.
	NR	Dermer G.B., et al., "Another Anniversary for the war on cancer," Biotechnology, 1994, 12:320.
	OR	Engel et al, "The B7-2 (B70) costimulatory molecule expressed by monocytes and activted B lymphocytes is the CD86 differentiation antigen," Blood, 1994, 84, 1402-1407.
	PR	Freeman G.J., et al., "CTLA-4 and CD28 MRNA are Coexpressed in Most T Cells After Activation," The Journal of Immunology, 1992, 149:3795-3801
	QR	Geenen V. and G. Kroemer, "Multiple Ways to Cellular Immune Tolerance," Immunology Today, 1993, 14:573.
	RR	Gimmi C.D., et al., "Human T-Cell Clonal Anergy is Induced by Antigen Presentation In the Absence of B7 Costimulation," Proc. Natl. Acad. Sci., 1993, 90:6586-6590.
	SR	Gribben J.G., et al., "CTLA-4 mediates antigen specific apoptosis of human T cells." Proc. Natl. Acad. Sci. USA, 1995, 92:811-815.
	TR	Grumet F.C., et al., "Soluble form of an HLA-B7 Class I Antigen Specifically Suppresses Humoral Alloimmunization." Human Immunology, 1994, 40:228-234.
	UR	Harding F.A., et al., "CD28 Mediated Signalling Co-stimulates Murine T Cells and Prevents Induction of Anergy in T Cell Clones." Nature, 1992, 356:607-609.
	VR	Hart D.N.J., et al., "B7/BB-1 is a Leucocyte Differentiation Antigen on Human Dendritic Cells Induced by Activation." Immunology, 1993, 79:616-620
PG	WR	Ionescu-Tirgoviste, et al, "Correlations between insulin antibodies and the HLA system in a group of Type I diabetic patients in Bucharest," Med. Interre, 1986, 24(1), 11-17.

Philip Gambel 2/14/05

	XR	Janeway C.A., Jr. and K. Bottomly, "Signals and Signs for Lymphocyte Responses," Cell, 1994, 76.275-285.
	YR	Jenkins M.K., "The Role of Cell Division in the Induction of Clonal Anergy." Immunology Today, 1992, 13:69.
	ZR	June C.H., et al., "The B7 and CD28 receptor families," Immunol Today, 1994, 15:321-331.
	AAR	Krummel M., et al., "CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation," J. Exp. Med. 1995, 182:459-466.
	BBR	LaSalle J.M., et al., "Early signaling defects in human T cells anergized by T cell presentation of autoantigen," J. Exp. Med., 1992, 176:177-186.
	CCR	Lenschow D.J., et al., "Long-Term Survival of Xenogeneic Pancreatic Islet Grafts Induced by CTLA-4Ig," Science, 1992, 257:789-795.
	DDR	Lenschow D.J., et al., "Expression and Functional Significance of an Additional Ligand for CTLA-4," Proc. Natl. Acad. Sci., USA.,1993, 90:11054-11058.
	EER	Lin H., et al., "Long-term Acceptance of Major Histocompatibility Complex Mismatched Cardiac Allografts Induced by CTLA-4-Ig Plus Donor Specific Transfusion," J. Exp. Med., 1993, 178:1801.
	FFR	Linsley, P.S., et al., "CTLA-4 is a Second Receptor for the B Cell Activation Antigen B7," J. Exp. Med., 1991, 174:561.
	GGR	Linsley P.S., et. al., "T-Cell Antigen CD28 Mediates Adhesion with B Cells by Interacting with Activation Antigen B7/BB-1." Proc. Natl. Acad. Sci., 1990, 87:5031-5035.
	HHR	Linsley, et al, "CD28 Engagement by B7/BB-1 Induces Transient Down-Regulation of CD28 Synthesis and Prolonged Unresponsiveness to CD28 Signaling," The Journal of Immunology, 1993, 150:3161-3169.
	IIR	Linsley, et al., "Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation," J. Exp. Med., 1991, 173:721-730.
	JJR	Linsley P.S., et. al., "Coexpression and Functional Cooperation of CTLA-4 and CD28 on Activated T Lymphocytes." J. Exp. Med., 1992, 176:1595-1604.
	KKR	Morton P.A., et al., "Differential effects of CTLA-4 substitutions on the binding of human CD80 (B7-1) and CD86 (B7-2)," J. Immunol., 1996,156:1047-1054.
	LLR	Nestle F.O., et al, "Characterization of dermal dendritic cells in psoriasis," J. Clin. Invest., 1994, 94: 202-209.
	MMR	Schwartz R.H., "Co-stimulation of T lymphocytes: The role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy," Cell, 1992, 71:1065-1068.
	NNR	Schwartz R.H., "A cell culture model for T lymphocyte clonal anergy," Science, 1990, 248:1349-1356.
	OOR	Selvakumar,A., et al., "Genomic organization and chromosomal location of the human gene encoding the B-lymphocyte activation antigen B7," Immunogenetics, 1992, 36:175-181
	PPR	Tan P., et al., "Induction of Alloantigen-specific Hyporesponsiveness in Human T Lymphocytes by Blocking Interaction of CD28 with Its Natural Ligand B7/BB1," J. Exp. Med., 1993, 177:165-173.
	QQR	Tivol E.A., et al., "Loss of CTLA-4 leads to massive lymphoproli-feration and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4," Immunity, 1995, 3:541-547.
	RRR	Turka L.A., et al., "T-cell activation by the CD28 ligand B7 is required for cardiac allograft rejection in vivo," Proc. Natl. Acad. Sci., USA, 1992, 89:11102-11105.
	SSR	Toubert A., et al., "Epitope mapping of an HLA-B27 monoclonal antibody that also reacts with a 35-kD bacterial out-membrane protein," Clin. Exp. Immunol., 1990, 82(1), 16-20.
	TTR	Toubert A., et al., "Epitope mapping of HLA-B27 and HLA-B7 antigens by using intradomain recombinants," J. Immunol., 1988, 141(7), 2503-9.
	UUR	Valle et al., "mAb 104, a new monoclonal antibody, recognizes the B7 antigen that is expressed on activated B cells and HTLV-1-transformed T cells," Immunol., 1990, 69(4), 531-535.
	VVR	Vandenberghe P., et al.. "Antibody and B7/BB1-mediated ligation of the CD28 receptor induces tyrosine phosphorylation in human T cells," J. Exp. Med., 1992, 175:951-960.
	WWR	van der Merwe, et al., "CD80 (B7-1) binds both CD28 and CTLA-4 with a low affinity and very fast kinetics," J. Exp. Med., 1997,185: 393-403.
	XXR	Weyl D., et al., "Epitope mapping of human monoclonal antibodies to HLA-B27 by using natural and mutated antigenic variants," Hum. Immunol., 1991, 31(4), 271-276.
	YYR	Zavazava N., et al, "Inhibition of anti-HLA-B7 alloreactive CTL by affinity-purified soluble HLA," Transplantation, 1991, 51(4), 838-42.

Examiner	Date Considered:
Phillip Gambel 1/14/05	

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.